Provided by Tiger Fintech (Singapore) Pte. Ltd.

Oculis

21.36
-0.1800-0.84%
Post-market: 21.900.5400+2.53%18:06 EDT
Volume:111.13K
Turnover:2.36M
Market Cap:1.12B
PE:-7.95
High:21.70
Open:21.70
Low:20.97
Close:21.54
52wk High:23.08
52wk Low:14.00
Shares:52.34M
Float Shares:40.92M
Volume Ratio:0.71
T/O Rate:0.27%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.6873
EPS(LYR):-2.3426
ROE:-83.96%
ROA:-29.71%
PB:6.22
PE(LYR):-9.12

Loading ...

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

GlobeNewswire
·
Yesterday

Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025

GlobeNewswire
·
Oct 14

Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025

GlobeNewswire
·
Oct 14

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

GlobeNewswire
·
Oct 09

2 Outstanding Healthcare Stocks to Buy and Hold for a Decade

Motley Fool
·
Oct 08

Chardan Research Adjusts Oculis Holding AG Price Target to $51 From $33, Maintains Buy Rating

MT Newswires Live
·
Oct 08

Oculis Holding Is Maintained at Buy by Chardan Capital

Dow Jones
·
Oct 08

Chardan Capital Reaffirms Their Buy Rating on Oculis Holding (OCS)

TIPRANKS
·
Oct 08

Oculis price target raised to $30 from $28 at BofA

TIPRANKS
·
Oct 07

Oculis Holding Ag : Bofa Global Research Raises Price Objective to $30 From $28

THOMSON REUTERS
·
Oct 07

Oculis Holding Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Oct 07

Oculis price target raised to $36 from $33 at H.C. Wainwright

TIPRANKS
·
Oct 07

Oculis Advances Privosegtor into Registrational Trials for Neuro-Ophthalmology

TIPRANKS
·
Oct 07

Oculis Holding (OCS) Gets a Buy from Bank of America Securities

TIPRANKS
·
Oct 07

Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy

GlobeNewswire
·
Oct 06

Oculis Publishes Notification of Transactions by Person Discharging Managerial Responsibilities

GlobeNewswire
·
Sep 27

AI Drives Surge! OCS Concept Stocks Collectively Soar While Shareholders Quietly Reduce Holdings

Deep News
·
Sep 22

Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS

GlobeNewswire
·
Sep 22

Phase III Clinical Trial Failure Sends Company Stock Plummeting 83%

Deep News
·
Sep 17

aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis

GlobeNewswire
·
Sep 15